Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1257007 | 0.81 | MAPT (0.50) | TSHRPLK1MAPTKDM4ENPC1 | |
| SCHEMBL28479419 | 0.80 | TSHR (0.46) | TSHRPLK1MAPTKDM4ENPC1 | |
| SCHEMBL19084410 | 0.80 | TSHR (0.46) | TSHRPLK1MAPTKDM4ENPC1 | |
| SCHEMBL17223287 | 0.80 | TSHR (0.55) | TSHRMAPTKDM4ENPC1RAB9A | |
| SCHEMBL2417181 | 0.79 | CHRNB2 (0.41) | TSHRMAPTKDM4ECA12CA1 | |
| SCHEMBL11666132 | 0.79 | PLK1 (0.48) | TSHRPLK1MAPTKDM4ENPC1 | |
| SCHEMBL6336946 | 0.79 | TSHR (0.44) | TSHRPLK1MAPTKDM4ENPC1 | |
| SCHEMBL12559200 | 0.79 | ALDH1A1 (0.50) | TSHRPLK1MAPTKDM4ENPC1 | |
| SCHEMBL19066808 | 0.77 | TSHR (0.43) | TSHRPLK1MAPTKDM4ENPC1 | |
| SCHEMBL15819569 | 0.77 | TSHR (0.47) | TSHRMAPTKDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197381-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-19 | — | — | US | disclosed |
| WO-2025090480-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-05-01 | — | — | WO | disclosed |
| US-12247021-B2 | Substituted tetrahydrofurans as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-03-11 | — | — | US | disclosed |
| EP-4506001-A2 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240391907-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-11-28 | — | — | US | disclosed |
| CN-114945566-B | Substituted tetrahydrofurans as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-11-12 | — | — | CN | disclosed |
| EP-4069691-B1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2024-09-18 | — | — | EP | disclosed |
| US-11919887-B2 | Substituted tetrahydrofurans as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-03-05 | — | — | US | disclosed |
| US-11834441-B2 | Substituted tetrahydrofurans as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834441-B2 | Substituted tetrahydrofurans as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-12-05 | — | — | US | disclosed |
| EP-1700856-A1 | THIAZOLE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-13 | — | — | EP | disclosed |
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| CN-1628111-A | 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON PHARMACEUTICAL CO (JP) | 2005-06-15 | — | — | CN | disclosed |
| EP-1489077-A1 | 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-12-22 | — | — | EP | disclosed |
| EP-1388534-A2 | 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | Allergan, Inc. (US) | 2004-02-11 | — | — | EP | disclosed |
| US-6403638-B1 | COMPOUND FOR USE IN TREATING SKIN DISEASES AND DISORDERS, AND FOR TREATING HYPERVITAMINOSIS A SYNDROME | ALLERGAN SALES, INC. | 2002-06-11 | — | — | US | disclosed |
| WO-2001070662-A2 | 2,4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | ALLERGAN , INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| EP-1117628-A1 | 2, 4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | Allergan Sales, Inc. (US) | 2001-07-25 | — | — | EP | disclosed |
| US-6147224-A | 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | ALLERGAN SALES, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| WO-2000020370-A1 | 2, 4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | ALLERGAN SALES, INC. (US) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247021-B2 | Substituted tetrahydrofurans as modulators of sodium channels | TRPV1, TRPA1, SCN2B | TSHR 3554/4885PLK1 3755/4885MAPT 1738/4885 |
| US-11834441-B2 | Substituted tetrahydrofurans as modulators of sodium channels | TRPV1, TRPA1, SCN2B | TSHR 3554/4885PLK1 3755/4885MAPT 1738/4885 |
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | GLP1R, GCGR, GPR119 | TSHR 82/4885PLK1 4869/4885MAPT 4833/4885 |
| US-20240391907-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | TRPV1, TRPA1, SCN2B | TSHR 3554/4885PLK1 3755/4885MAPT 1738/4885 |
| US-11919887-B2 | Substituted tetrahydrofurans as modulators of sodium channels | TRPV1, TRPA1, SCN2B | TSHR 3554/4885PLK1 3755/4885MAPT 1738/4885 |
| US-20250197381-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | TRPV1, TRPA1, SCN2B | TSHR 3554/4885PLK1 3755/4885MAPT 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.